fashion -WSS

fashion

author：knowledge 2025-09-30 12:10:53 - browse：1

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Shionogi licenses Pompe disease therapy from Maze Therapeutics

focus

entertainment

WSS

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Readout LOUD podcast: What to know about H5N1 bird flu

Medicare says breakthrough device reimbursement rule to come by summer

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Making AI in medicine accessible to smaller, and rural hospitals

leisure time

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

Elevance, private equity launch primary care company

Sports medicine is finally prioritizing gender equality

Bird flu outbreak in cows is latest avian flu curveball

Peter Hotez and the public health issue of online harassment

Readout LOUD podcast: What to know about H5N1 bird flu

Medical leaders decry Supreme Court decision on affirmative action

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Cancer drug shortages should be causing more outrage

Readout LOUD podcast: brain research, obesity drug sales, Novartis

knowledge

Readout LOUD podcast: What to know about H5N1 bird flu

CDC wastewater surveillance dashboard to track bird flu hotspots

After gene therapy, two congenitally deaf children hear for the first time

Readout LOUD podcast: What to know about H5N1 bird flu

Brain worms: The science behind RFK Jr.'s parasitic infection

How to improve immunocompromised access to mAb treatments

Wikipedia

focus

entertainment

focus